News
Vertex preps FDA filing for IgAN drug after phase 3 readout
Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.
R&D
Treating genetic disease at scale with tRNA, with Michelle W...
Michelle Werner, CEO of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.
News
BioNTech bigwigs will step down to form new mRNA company
The co-founders of mRNA specialist BioNTech – husband and wife team Uğur Şahin and Özlem Türeci – have said they are leaving to set up a new company.
News
BMS eyes another celmod filing in myeloma after phase 3 win
Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.
News
FDA cuts testing requirements for biosimilars once again
The FDA has issued additional guidance that aims to make it easier for drugmakers to bring biosimilars of patent-expired biologic drugs to market.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
